Low expression of Mel-18 predicts poor prognosis in patients with breast cancer

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2361-2369

  Guo, B H ^a,b   Zhang, X ^a   Zhang, H Z ^a   Lin, H L ^b   Feng, Y ^a   Shao, J Y ^a   Huang, W L ^a   Kung, H F ^b   Zeng, M S ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bmi 1; Breast cancer; Mel 18; Polycomb group proteins

Indexed keywords

MELANOMA NUCLEAR PROTEIN 18; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REPRESSOR PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649461311     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq241     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
3. Jacobs JJ, van Lohuizen M. Cellular memory of transcriptional states by Polycomb-group proteins. Semin Cell Dev Biol 1999; 10: 227-235.
4. Kanno M, Hasegawa M, Ishida A et al. mel-18, a Polycomb group-related mammalian gene, encodes a transcriptional negative regulator with tumor suppressive activity. EMBO J 1995; 14: 5672-5678.
5. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6: 846-856.
6. Kajiume T, Ninomiya Y, Ishihara H et al. Polycomb group gene mel-18 modulates the self-renewal activity and cell cycle status of hematopoietic stem cells. Exp Hematol 2004; 32: 571-578.
7. Kajiume T, Ohno N, Sera Y et al. Reciprocal expression of Bmi1 and Mel-18 is associated with functioning of primitive hematopoietic cells. Exp Hematol 2009; 37: 857-866, e852.
8. Wiederschain D, Chen L, Johnson B et al. Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. Mol Cell Biol 2007; 27: 4968-4979.
9. Guo WJ, Datta S, Band V, Dimri GP. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell 2007; 18: 536-546.
10. Ishida A, Asano H, Hasegawa M et al. Cloning and chromosome mapping of the human Mel-18 gene which encodes a DNA-binding protein with a new 'RING-finger' motif. Gene 1993; 129: 249-255.
11. Matsuo F, Yano K, Saito H et al. Mutation analysis of the mel-18 gene that shows decreased expression in human breast cancer cell lines. Breast Cancer 2002; 9: 33-38.
12. Guo WJ, Zeng MS, Yadav A et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res 2007; 67: 5083-5089.
13. Lee JY, Jang KS, Shin DH et al. Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer. Cancer Res 2008; 68: 4201-4209.
14. Sanchez-Beato M, Sanchez E, Gonzalez-Carrero J et al. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol 2006; 19: 684-694.
15. Wang W, Yuasa T, Tsuchiya N et al. The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance. Int J Cancer 2009; 15: 2836-2843.
16. Wang W, Lin T, Huang J et al. Analysis of Mel-18 expression in prostate cancer tissues and correlation with clinicopathologic features. Urol Oncol 2009 Apr 21. [Epub ahead of print].
17. Zhang XW, Sheng YP, Li Q et al. BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer 9: 40.
18. Tagawa M, Sakamoto T, Shigemoto K et al. Expression of novel DNA-binding protein with zinc finger structure in various tumor cells. J Biol Chem 1990; 265: 20021-20026.
19. Dukers DF, van Galen JC, Giroth C et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004; 164: 873-881.
20. Vekony H, Roser K, Loning T et al. Deregulated expression of p16INK4a and p53 pathway members in benign and malignant myoepithelial tumours of the salivary glands. Histopathology 2008; 53: 658-666.
21. Vekony H, Raaphorst FM, Otte AP et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol 2008; 61: 744-749.
22. Borgquist S, Holm C, Stendahl M et al. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 2008; 61: 197-203.
23. Jacquemier J, Charafe-Jauffret E, Monville F et al. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 2009; 11: R23.
24. Yu J, Cheng YY, Tao Q et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009; 136: 640-651e641.
25. Silva J, Garcia JM, Pena C et al. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res 2006; 12: 6929-6936.
26. Zhong N, Radu G, Ju W, Brown WT. Novel progerin-interactive partner proteins hnRNP E1, EGF, Mel 18, and UBC9 interact with lamin A/C. Biochem Biophys Res Commun 2005; 338: 855-861.
27. Sanchez-Beato M, Sanchez E, Garcia JF et al. Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors. J Pathol 2004; 204: 528-537.
28. Voncken JW, Schweizer D, Aagaard L et al. Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status. J Cell Sci 1999; 112(Pt 24): 4627-4639.
29. Noguchi K, Shiurba R, Higashinakagawa T. Nuclear translocation of mouse polycomb m33 protein in regenerating liver. Biochem Biophys Res Commun 2002; 291: 508-515.
30. Elderkin S, Maertens GN, Endoh M et al. A phosphorylated form of Mel-18 targets the Ring1B histone H2A ubiquitin ligase to chromatin. Mol Cell 2007; 28: 107-120.
31. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-187.